Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, von-Siebold-Str. 5, 37075, Göttingen, Germany.
Eur Arch Psychiatry Clin Neurosci. 2018 Dec;268(8):809-817. doi: 10.1007/s00406-017-0840-8. Epub 2017 Sep 22.
Electroconvulsive therapy (ECT) is the most effective therapy for severe depressive disorders. Though there are known clinical predictors of response (e.g., higher age, presence of psychotic symptoms), there is a lack of knowledge concerning the impact of patients' expectations on treatment outcome and tolerability in terms of possible placebo/nocebo effects. In 31 patients with unipolar or bipolar depressive disorder, we used a questionnaire to investigate the patients' expectations of ECT effectiveness and tolerability prior to and in the course of the treatment. Additionally, the questionnaire was used after the ECT course for a final assessment. Depressive symptoms and putative side-effects were measured at each time point. General linear models were used to analyze the course of depressive symptoms and patients' expectation of ECT effectiveness and tolerability. ECT significantly reduced depressive symptoms with large effect sizes. Patients' rating of ECT effectiveness decreased in parallel: While responders' rating of ECT effectiveness remained stable on a high level, non-responders' rating decreased significantly. Group difference was significant after, but not prior to and during the treatment. Regarding tolerability, there was a (temporary) significant increase in the severity of self-rated symptoms such as headache and memory impairment. In contrast, patients' expectation and assessment of ECT tolerability remained unchanged, and their expectations prior to ECT had no impact on the occurrence of side-effects. These findings contradict the presence of relevant placebo/nocebo effects in the context of ECT when investigating a population of mostly chronic or treatment resistant patients with moderate to severe depressive disorder.
电抽搐治疗(ECT)是治疗重度抑郁障碍最有效的方法。虽然已经有一些已知的临床预测因素(例如,年龄较高,存在精神病症状),但是对于患者的期望对治疗结果和耐受性的影响,以及可能的安慰剂/反安慰剂效应方面的知识仍然不足。在 31 名患有单相或双相抑郁障碍的患者中,我们使用问卷在治疗前和治疗过程中调查了患者对 ECT 有效性和耐受性的期望。此外,在 ECT 疗程结束后,我们使用该问卷进行最终评估。在每个时间点测量抑郁症状和疑似副作用。使用一般线性模型分析抑郁症状的变化过程和患者对 ECT 有效性和耐受性的期望。ECT 显著降低了抑郁症状,其效果明显。患者对 ECT 有效性的评价也随之降低:而 responders 对 ECT 有效性的评价保持在高水平稳定,而非 responders 的评价则显著降低。这种差异在治疗后显著,但在治疗前和治疗期间不显著。关于耐受性,自我报告的症状(如头痛和记忆障碍)严重程度有(暂时)显著增加。相比之下,患者对 ECT 耐受性的期望和评估保持不变,ECT 前的期望对副作用的发生没有影响。这些发现与 ECT 中存在相关安慰剂/反安慰剂效应的情况相矛盾,因为我们调查的是一群患有中度至重度抑郁障碍的慢性或治疗抵抗性患者。